Correo Electrónico
DNINFOA - SIA
Bibliotecas
Convocatorias
Identidad U.N.
Publicado
Clinical practice guideline for screening of patients at risk of colonization by carbapenemase-producing Enterobacterales and the treatment of infections caused by these bacteria
Guía de práctica clínica para la tamización de pacientes con riesgo de colonización por Enterobacterales productores de carbapenemasas y el manejo de infecciones causadas por estas bacterias
Palabras clave:
Clinical guidelines as Topic, Enterobacteriaceae, Enterobacteriaceae Infections, Polymyxins, Klebsiella pneumoniae, Drug resistance, Bacterial (en)Guías de práctica clínica como asunto, Enterobacterales, Enterobacteriaceae, Poliximinas, Klebsiella pneumoniae, Farmacorresistencia bacteriana (es)
Descargas
Carbapenemase-producing Enterobacterales (CPE) infections have increased in recent years. Colombia has become an endemic country for this group of microorganisms, and the infections they cause have a serious impact in terms of morbidity and mortality. The early identification of CPE carriers who are admitted to health care centers as patients is necessary to implement adequate isolation and infection control measures to limit the spread of this type of microorganisms in hospitals. Furthermore, treating these infections is a challenging task due to the limited therapeutic alternatives available and the fact that there are only a few studies proving their effectiveness in this setting.
Therefore, the objective of the present work is to develop a clinical practice guideline (CPG) for the screening of patients at risk of CPE colonization and the treatment of inpatients with suspected or confirmed infections caused by this type of bacteria through a CPG adaptation process based on the ADAPTE methodology. With this purpose in mind, evidence-informed recommendations for the screening and timely identification of CPE carriers admitted to hospitals are made, as well as for the adequate pharmacological treatment of CPE infections in this context.
Taking this into account, the objective of this work is to develop a clinical practice guideline (CPG) for the screening of patients at risk of CPE colonization and for the management of inpatients with suspected or confirmed infections caused by this type of enterobacteriaceae by means of a CPGs adaptation process based on the ADAPTE methodology. With this purpose in mind, evidence-informed recommendations for the screening and timely identification of CPE carriers admitted to hospitals are made, as well as for the adequate pharmacological management of CPE infections in this setting.
Las infecciones por Enterobacterales productores de carbapenemasas (EPC) han aumentado en los últimos años. Colombia se ha convertido en un país endémico para este grupo de microorganismos y las infecciones que causan tienen un impacto importante en términos de morbimortalidad. La identificación temprana de los portadores de EPC que ingresan como pacientes a las instituciones de salud es necesaria para implementar medidas de aislamiento y control de infecciones adecuadas que limiten la diseminación de este tipo de microorganismos en los hospitales. Además, el tratamiento de estas infecciones es difícil debido a las limitadas alternativas terapéuticas disponibles y la escasez de estudios que demuestren su efectividad en este escenario.
Por lo anterior, el objetivo del presente trabajo es desarrollar una guía de práctica clínica (GPC) para la tamización de pacientes con riesgo de colonización por EPC y para el manejo de pacientes con infecciones, ya sea sospechadas o confirmadas, causadas por este tipo de bacterias, mediante un proceso de adaptación de GPC basado en la metodología ADAPTE. Con este propósito en mente, se hacen recomendaciones informadas en evidencia para realizar la tamización y oportuna identificación de portadores de EPC admitidos en instituciones hospitalarias, así como para el adecuado manejo farmacológico de las infecciones por CPE en este escenario.
Por lo anterior, el objetivo del presente trabajo es desarrollar una guía de práctica clínica (GPC) para la tamización de pacientes con riesgo de colonización por EPC y para el manejo de pacientes con infecciones, ya sea sospechadas o confirmadas, causadas por este tipo de bacterias, mediante un proceso de adaptación de GPC basado en la metodología ADAPTE. Con este propósito en mente, se hacen recomendaciones informadas en evidencia para realizar la tamización y oportuna identificación de portadores de EPC admitidos en instituciones hospitalarias, así como para el adecuado manejo farmacológico de las infecciones por EPC en este escenario.
Descargas
Citas
Carlet J, Jarlier V, Harbarth S, Voss A, Goossens H, Pittet D. Ready for a world without antibiotics? The Pensieres Antibiotic Resistance Call to Action. Antimicrob Resist Infect Control. 2012;1(1):11. https://doi.org/f4fx94.
Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016;3(1):15-21. https://doi.org/f789.
Sánchez MB. Antibiotic resistance in the opportunistic pathogen Stenotrophomonas maltophilia. Front Microbiol 2015;6:658. https://doi.org/f79b.
Patel G, Bonomo RA. “Stormy waters ahead”: global emergence of carbapenemases. Front Microbiol. 2013;4:48. https://doi.org/ghzj74.
Meletis G, Exindari M, Vavatsi N, Sofianou D, Diza E. Mechanisms responsible for the emergence of carbapenem resistance in Pseudomonas aeruginosa. Hippokratia. 2012;16(4):303-7.
Poirel L, Pitout JD, Nordmann P. Carbapenemases: molecular diversity and clinical consequences. Future Microbiol. 2007;2(5):501-12. https://doi.org/d83qfb.
Villegas MV, Lolans K, Correa A, Suarez CJ, Lopez JA, Vallejo M, et al. First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother. 2006;50(8):2880-2. https://doi.org/brqfr9.
Suay-Garcia B, Pérez-Gracia MT. Present and Future of Carbapenem-resistant Enterobacteriaceae (CRE) Infections. Antibiotics (Basel). 2019;8(3):122. https://doi.org/ghxj3t.
Livermore DM, Nicolau DP, Hopkins KL, Meunier D. Carbapenem-Resistant Enterobacterales, Carbapenem Resistant Organisms, Carbapenemase-Producing Enterobacterales, and Carbapenemase-Producing Organisms: Terminology Past its “Sell-By Date” in an Era of New Antibiotics and Regional Carbapenemase Epidemiology. Clin Infect Dis. 2020;71(7):1776-82. https://doi.org/f79f.
World Health Organization (WHO). publishes list of bacteria for which new antibiotics are urgently needed. Geneva: WHO; 2017.
Ramos-Castaneda JA, Ruano-Ravina A, Barbosa-Lorenzo R, Paillier-Gonzalez JE, Saldana-Campos JC, Salinas DF, et al. Mortality due to KPC carbapenemase-producing Klebsiella pneumoniae infections: Systematic review and meta-analysis: Mortality due to KPC Klebsiella pneumoniae infections. J Infect. 2018;76(5):438-48. https://doi.org/gdf788.
Martin A, Fahrbach K, Zhao Q, Lodise T. Association Between Carbapenem Resistance and Mortality Among Adult, Hospitalized Patients With Serious Infections Due to Enterobacteriaceae: Results of a Systematic Literature Review and Meta-analysis. Open Forum Infect Dis. 2018;5(7):ofy150. https://doi.org/gd3bhg.
Gualtero S, Valderrama S, Valencia M, Rueda D, Muñoz-Velandia O, Ariza B, et al. Factors associated with mortality in Infections caused by Carbapenem-resistant Enterobacteriaceae. J Infect Dev Ctries. 2020;14(6):654-9. https://doi.org/f79g.
Cienfuegos-Gallet AV, Ocampo-de Los Ríos AM, Sierra-Viana P, Ramírez-Brinez F, Restrepo-Castro C, Roncancio-Villamil G, et al. Risk factors and survival of patients infected with carbapenem-resistant Klebsiella pneumoniae in a KPC endemic setting: a case-control and cohort study. BMC Infect Dis. 2019;19(1):830. https://doi.org/f79h.
Bartsch SM, McKinnell JA, Mueller LE, Miller LG, Gohil SK, Huang SS, et al. Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect. 2017;23(1):48.e9-e16. https://doi.org/f9v3gj.
Vargas-Alzate CA, Higuita-Gutiérrez LF, Jiménez-Quiceno JN. Costos médicos directos de las infecciones del tracto urinario por bacilos Gram negativos resistentes a betalactámicos en un hospital de alta complejidad de Medellín, Colombia. Biomédica. 2019;39(Suppl 1):35-49. https://doi.org/f79j.
Fervers B, Burgers JS, Haugh MC, Latreille J, Mlika-Cabanne N, Paquet L, et al. Adaptation of clinical guidelines: literature review and proposition for a framework and procedure. Int J Qual Health Care. 2006;18(3):167-76. https://doi.org/dzr2qh.
AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care. 2003;12(1):18-23. https://doi.org/b4hkt8.
World Health Organization (WHO). Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities. Geneva: WHO; 2017.
Ambretti S, Bassetti M, Clerici P, Petrosillo N, Tumietto F, Viale P, et al. Screening for carriage of carbapenem-resistant Enterobacteriaceae in settings of high endemicity: a position paper from an Italian working group on CRE infections. Antimicrob Resist Infect Control. 2019;8:136. https://doi.org/f79k.
Solter E, Adler A, Rubinovitch B, Temkin E, Schwartz D, Ben-David D, et al. Israeli National Policy for Carbapenem-Resistant Enterobacteriaceae Screening, Carrier Isolation and Discontinuation of Isolation. Infect Control Hosp Epidemiol. 2018;39(1):85-9. https://doi.org/f79m.
Lepelletier D, Berthelot P, Lucet JC, Fournier S, Jarlier V, Grandbastien B. French recommendations for the prevention of ‘emerging extensively drug-resistant bacteria’ (eXDR) cross-transmission. J Hosp Infect 2015;90(3):186-95. https://doi.org/f7ftcw.
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-94. https://doi.org/cdgpns.
Grupo para el control de la Resistencia bacteriana de Bogotá (GREBO). Boletín informativo GREBO Numero 10. Resultados de la vigilancia de la resistencia bacteriana Año 2017. Bogotá D.C.: GREBO; 2019 [cited 2019 Nov 12]. Available from: https://bit.ly/2R0zhYi.
Ovalle MV, Saavedra SY, González MN, Hidalgo AM, Duarte C, Beltrán M. Resultados de la vigilancia nacional de la resistencia antimicrobiana de enterobacterias y bacilos Gram negativos no fermentadores en infecciones asociadas a la atención de salud, Colombia, 2012-2014. Biomédica. 2017;37(4):473-85. https://doi.org/f8rb.
Colombia. Instituto Nacional de Salud (INS). Informe de resultados de la vigilancia por laboratorio de resistencia antimicrobiana en infecciones asociadas a la atención en salud (IAAS) 2018. Bogotá D.C.: INS; 2019 [cited 2020 Mar 17]. Available from: https://bit.ly/3nmHwdr.
Centers for Disease Control and Prevention (CDC). Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE). Druid Hills: CDC; 2015.
Richter SS, Marchaim D. Screening for carbapenem-resistant Enterobacteriaceae: Who, When, and How? Virulence 2017;8(4):417-26. https://doi.org/f9zw.
Friedman ND, Carmeli Y, Walton AL, Schwaber MJ. Carbapenem-Resistant Enterobacteriaceae: A Strategic Roadmap for Infection Control. Infect Control Hosp Epidemiol. 2017;38(5):580-94. https://doi.org/f9zv.
Viale P, Tumietto F, Giannella M, Bartoletti M, Tedeschi S, Ambretti S, et al. Impact of a hospital-wide multifaceted programme for reducing carbapenem-resistant Enterobacteriaceae infections in a large teaching hospital in northern Italy. Clin Microbiol Infect. 2015;21(3):242-7. https://doi.org/f69wdb.
Hayden MK, Lin MY, Lolans K, Weiner S, Blom D, Moore NM, et al. Prevention of colonization and infection by Klebsiella pneumoniae carbapenemase-producing enterobacteriaceae in long-term acute-care hospitals. Clin Infect Dis. 2015;60(8):1153-61. https://doi.org/f69xqp.
Gagliotti C, Cappelli V, Carretto E, Marchi M, Pan A, Ragni P, et al. Control of carbapenemase-producing Klebsiella pneumoniae: a region-wide intervention. Euro Surveill. 2014;19(43):20943. https://doi.org/f9xx.
Ciobotaro P, Oved M, Nadir E, Bardenstein R, Zimhony O. An effective intervention to limit the spread of an epidemic carbapenem-resistant Klebsiella pneumoniae strain in an acute care setting: from theory to practice. Am J Infect Control. 2011;39(8):671-7. https://doi.org/dv9m3v.
Cronin KM, Poy Lorenzo YS, Olenski ME, Bloch AE, Visvanathan K, Waters MJ, et al. Risk factors for KPC-producing Enterobacteriaceae acquisition and infection in a healthcare setting with possible local transmission: a case-control study. J Hosp Infect. 2017;96(2):111-5. https://doi.org/f975zt.
Lin MY, Lyles-Banks RD, Lolans K, Hines DW, Spear JB, Petrak R, et al. The importance of long-term acute care hospitals in the regional epidemiology of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis 2013;57(9):1246-52. https://doi.org/f5c5d3.
Mathers AJ, Vegesana K, German-Mesner I, Ainsworth J, Pannone A, Crook DW, et al. Risk factors for Klebsiella pneumoniae carbapenemase (KPC) gene acquisition and clinical outcomes across multiple bacterial species. J Hosp Infect. 2020;104(4):456-68. https://doi.org/f9zx.
Song JY, Jeong IS. Validation of a carbapenem-resistant Enterobacteriaceae colonization risk prediction model: A retrospective cohort study in Korean intensive care units. Am J Infect Control. 2019;47(12):1436-42. https://doi.org/f9zz.
Velez JD, Orrego M, Montes S, Tafur E, Parra-Lara LG, Castro A, et al. Factors Associated with the Persistence of Colonization by Multidrug-Resistant Organisms in Cali, Colombia. Open Forum Infect Dis. 2019;6(Suppl 2):S258. https://doi.org/f9z2.
Centers for Disease Control (CDC). Laboratory Protocol for Detection of Carbapenem-Resistant or Carbapenemase-Producing, Klebsiella spp. and E. coli from Rectal Swabs. Druid Hills: CDC; 2020.
Giani T, Tascini C, Arena F, Ciullo I, Conte V, Leonildi A, et al. Rapid detection of intestinal carriage of Klebsiella pneumoniae producing KPC carbapenemase during an outbreak. J Hosp Infect. 2012;81:119-22. https://doi.org/f9z3.
Blackburn J, Tsimiklis C, Lavergne V, Pilotte J, Grenier S, Gilbert A, et al. Carbapenem disks on MacConkey agar in screening methods for detection of carbapenem-resistant Gram-negative rods in stools. J Clin Microbiol. 2013;51(1):331-3. https://doi.org/f9z5.
Zhong H, Wu ML, Feng WJ, Huang SF, Yang P. Accuracy and applicability of different phenotypic methods for carbapenemase detection in Enterobacteriaceae: A systematic review and meta-analysis. J Glob Antimicrob Resist. 2020;21:138-47. https://doi.org/ghv7hh.
Nordmann P, Poirel L, Dortet L. Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2012;18(9):1503-7. https://doi.org/f3789x.
Dortet L, Tande D, de Briel D, Bernabeu S, Lasserre C, Gregorowicz G, et al. MALDI-TOF for the rapid detection of carbapenemase-producing Enterobacteriaceae: comparison of the commercialized MBT STAR(R)-Carba IVD Kit with two in-house MALDI-TOF techniques and the RAPIDEC(R) CARBA NP. J Antimicrob Chemother. 2018;73(9):2352-9. https://doi.org/gd7jnj.
Amladi AU, Sudarsanam TD, Kandasamy S, Kekre N, Veeraraghavan B, Sahni R. Evaluation of CHROMagarTMmSuperCARBATM as a Phenotypic Test for Detection of Carbapenemase Producing Organisms. J Clin Diagn Res. 2019;13(9):DC11-5. https://doi.org/f92c.
Papadimitriou-Olivgeris M, Bartzavali C, Christofidou M, Bereksi N, Hey J, Zambardi G, et al. Performance of chromID(R) CARBA medium for carbapenemases-producing Enterobacteriaceae detection during rectal screening. Eur J Clin Microbiol Infect Dis. 2014;33(1):35-40. https://doi.org/f5n8m8.
Josa DF, Bustos G, Torres IC, Esparza G. Evaluación de tres métodos de tamizaje para detección de Enterobacteriaceae productoras de carbapenemasas en hisopados rectales. Rev Chil. Infectol. 2018;35(3):253-61. https://doi.org/f92j.
Villegas MV, Jiménez A, Esparza G, Appel TM. Carbapenemase-producing Enterobacteriaceae: A diagnostic, epidemiological and therapeutic challenge. Infectio. 2019;23(4):388-98. https://doi.org/f92k.
Tamma PD, Simner PJ. Phenotypic Detection of Carbapenemase-Producing Organisms from Clinical Isolates. J Clin Microbiol. 2018;56(11):e01140-18. https://doi.org/gfk82p.
He Q, Chen W, Huang L, Lin Q, Zhang J, Liu R, et al. Performance evaluation of three automated identification systems in detecting carbapenem-resistant Enterobacteriaceae. Ann Clin Microbiol Antimicrob. 2016;15(1):40. https://doi.org/f92w.
Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17(7):726-34. https://doi.org/ghzb2n.
Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med. 1989;87(5):540-6. https://doi.org/fbvj9j.
Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31(2):e00079-17. https://doi.org/gc9hpp.
Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. Antibiotic Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae: Systematic Evaluation of the Available Evidence. Antimicrob Agents Chemother. 2014;58(2):654-63. https://doi.org/f5rc6q.
Zusman O, Avni T, Leibovici L, Adler A, Friberg L, Stergiopoulou T, et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother. 2013;57(10):5104-11. https://doi.org/f23svq.
van Duin D. Carbapenem-resistant Enterobacteriaceae: What we know and what we need to know. Virulence. 2017;8(4):379-82. https://doi.org/f922.
Machuca I, Gutiérrez-Gutiérrez B, Rivera-Espinar F, Cano A, Gracia-Ahufinger I, Guzmán-Puche J, et al. External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteraemia cohort: the prognostic significance of colistin resistance. Int J Antimicrob Agents. 2019;54(4):442-8. https://doi.org/f923.
Cunha CB, Cunha BA. Antibiotic Essentials. 16th ed. New Dehli: Jaypee Brothers MEdical Publishing; 2019.
Shirley M. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections. Drugs. 2018;78(6):675-92. https://doi.org/gdhcps.
Buckman SA, Krekel T, Muller AE, Mazuski JE. Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections. Expert Opin Pharmacother. 2016;17(17):2341-9. https://doi.org/f97v.
Tuon FF, Rocha JL, Formigoni-Pinto MR. Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review. Infection. 2018;46(2):165-81. https://doi.org/gdbk84.
Sy SKB, Zhuang L, Sy S, Derendorf H. Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development. Clin Pharmacokinet. 2019;58:545-64. https://doi.org/f97w.
Alidjanov JF, Fritzenwanker M, Hoffman I, Wagenlehner FM. Ceftazidime-avibactam: novel antimicrobial combination for the treatment of complicated urinary tract infections. Future Microbiol. 2017;12: 655-70. https://doi.org/f97x.
van Duin D, Bonomo RA. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation beta-Lactam/beta-Lactamase Inhibitor Combinations. Clin Infect Dis. 2016;63(2):234-41. https://doi.org/f8zq2r.
Wenzler E, Bunnell KL, Bleasdale SC, Benken S, Danziger LH, Rodvold KA. Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration. Antimicrob Agents Chemother. 2017;61(7):e00464-17. https://doi.org/gbr7w4.
Jaruratanasirikul S, Thengyai S, Wongpoowarak W, Wattanavijitkul T, Tangkitwanitjaroen K, Sukarnjanaset W, et al. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units. Antimicrob Agents Chemother. 2015;59(6):2995-3001. https://doi.org/f7k8pj.
Gilbert DN. Meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides. Clin Infect Dis. 1997;24(5):816-9. https://doi.org/chxk7t.
Dorn C, Petroff D, Neumann N, Kratzer A, El-Najjar N, Dietrich A, et al. Plasma and tissue pharmacokinetics of fosfomycin in morbidly obese and non-obese surgical patients: a controlled clinical trial. J Antimicrob Chemother. 2019;74(8):2335-40. https://doi.org/gbdn.
Kaye KS, Rice LB, Dane AL, Stus V, Sagan O, Fedosiuk E, et al. Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial. Clin Infect Dis. 2019;69(12):2045-56. https://doi.org/gbdp.
Cunha BA. Antibiotic Essentials. 14th ed. London: Jaypee Brothers Medical Publishers; 2015.
Onorato L, Di Caprio G, Signoriello S, Coppola N. Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis. Int J Antimicrob Agents. 2019;54(6):735-40. https://doi.org/f924.
Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, et al. Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. Clin Infect Dis. 2016;63(12):1615-8. https://doi.org/f9nvj6.
van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, et al. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis. 2018;66(2):163-71. https://doi.org/gcx9sk.
Tumbarello M, Trecarichi EM, Corona A, De Rosa FG, Bassetti M, Mussini C, et al. Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019;68(3):355-64. https://doi.org/gdpztk.
Jorgensen SCJ, Trinh TD, Zasowski EJ, Lagnf AM, Bhatia S, Melvin SM, et al. Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Open Forum Infect Dis. 2019;6(12):ofz522. https://doi.org/gg5fcz.
King M, Heil E, Kuriakose S, Bias T, Huang V, El-Beyrouty C, et al. Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections. Antimicrob Agents Chemother. 2017;61(7). https://doi.org/gbsd6h.
Tsolaki V, Mantzarlis K, Mpakalis A, Malli E, Tsimpoukas F, Tsirogianni A, et al. Ceftazidime-Avibactam To Treat Life-Threatening Infections by Carbapenem-Resistant Pathogens in Critically Ill Mechanically Ventilated Patients. Antimicrob Agents Chemother. 2020;64(3):e02320. https://doi.org/f97q.
Alraddadi BM, Saeedi M, Qutub M, Alshukairi A, Hassanien A, Wali G. Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae. BMC Infect Dis. 2019;19: 772. https://doi.org/f97r.
Bowers DR, Huang V. Emerging Issues and Treatment Strategies in Carbapenem-Resistant Enterobacteriaceae (CRE). Curr Infect Dis Rep. 2016;18(12):48. https://doi.org/f97s.
Falcone M, Viale P, Tiseo G, Pai M. Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia. Expert Opin Drug Metab Toxicol. 2018;14(3):331-40. https://doi.org/f97t.
Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Arlington: Infectious Diseases Society of America; 2020.
Appel TM, Mojica MF, De La Cadena E, Pallares CJ, Radice MA, Castaneda-Mendez P, et al. In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries. Antibiotics (Basel). 2020;9(2):62. https://doi.org/gbdr.
Ni W, Han Y, Liu J, Wei C, Zhao J, Cui J, et al. Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 2016;95(11):e3126. https://doi.org/gjkxkw.
Rodríguez JY, Valderrama SL, Osorio-Pinzón J, Cataño JC, Cortés JA, Arévalo-Mora L, et al. Tigeciclina en infecciones de piel y tejidos blandos complicadas. Infectio. 2017;21(4):223-32.
Osorio J, Castaño JC, Jiménez MF, Cortés JA, Martínez-Buitrago E, Ardévalo-Mora L, et al. Tigeciclina en infecciones intraabdominales complicadas. Infectio. 2017;21(4):234-42.
Xia G, Jiang R. Clinical study on the safety and efficacy of high-dose tigecycline in the elderly patients with multidrug-resistant bacterial infections: A retrospective analysis. Medicine (Baltimore). 2020;99(10):e19466. https://doi.org/gjnmvx.
Hung WY, Kogelman L, Volpe G, Iafrati M, Davidson L. Tigecycline-induced acute pancreatitis: case report and literature review. Int J Antimicrob Agents. 2009;34(5):486-9. https://doi.org/bnk27f.
Satlin MJ, Kubin CJ, Blumenthal JS, Cohen AB, Furuya EY, Wilson SJ, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother. 2011;55(12):5893-9. https://doi.org/c8nk92.
van Duin D, Cober E, Richter SS, Perez F, Kalayjian RC, Salata RA, et al. Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2015;70(4):1203-11. https://doi.org/gwd5.
Molina J, Cordero E, Palomino J, Pachón J. Aminoglucósidos y polimixinas. Enferm Infecc Microbiol Clin. 2009;27(3):178-88. https://doi.org/c3smq3.
Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandosky G, Sordillo E, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agenst Chemother. 2012;56(4):2108-13. https://doi.org/fzdqs9.
Zusman O, Altunin S, Koppel F, Dishon-Benattar Y, Gedik H, Paul M. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother. 2017;72(1):29-39. https://doi.org/f9tn3v.
Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17(12):1798-803. https://doi.org/d5wq44.
Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10-39. https://doi.org/ggjbgg.
Satlin MJ, Lewis JS, Weinstein MP, Patel J, Humphries RM, Kahlmeter G, et al. Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) position statements on polymyxin B and colistin clinical breakpoints. Clin Infect Dis. 2020;71(9):e523-9. https://doi.org/gh9psf.
Miglis C, Rhodes NJ, Avedissian SN, Kubin CJ, Yin MT, Nelson BC, et al. Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients. Antimicrob Agents Chemother. 2018;62(3):e01475. https://doi.org/gdbfbt.
Osorio J, Barreto J, Samboni CF, Cándelo LA, Álvarez LC, Benavidez S, et al. Factores asociados a nefrotoxicidad por polimixina B en un hospital universitario de Neiva, Colombia. 2011-2015. Rev Chil Infectol. 2017;34(1):7-13. https://doi.org/gbjr.
Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem. J Clin Pharmacol. 2003;43(10):1116-23. https://doi.org/djj8b3.
Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect. 2011;17(8):1135-41. https://doi.org/fm24vx.
Li YY, Wang J, Wang R, Cai Y. Double-carbapenem therapy in the treatment of multidrug resistant Gram-negative bacterial infections: a systematic review and meta-analysis. BMC Infect Dis. 2020;20(1):408. https://doi.org/gbjs.
Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66(7):719-25. https://doi.org/f43b2h.
Licencia
Derechos de autor 2021 Revista de la Facultad de Medicina
Esta obra está bajo una licencia Creative Commons Reconocimiento 3.0 Unported.
-
